Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
ID: 350826Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350826

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-313.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at supporting the validation of biomarkers and related assays for cancer detection, diagnosis, prognosis, and treatment monitoring. This initiative, managed by the National Cancer Institute (NCI), is structured in two phases: the UH2 phase focuses on analytical validation of assays to be completed within two years, while the UH3 phase supports clinical validation for up to three years, emphasizing the need for multidisciplinary collaboration among researchers and clinicians. With an award ceiling of $275,000 for the UH2 phase and up to $250,000 per year for the UH3 phase, interested applicants must submit their proposals by October 14, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-313-Full-Announcement.html
    PAR-23-313.html
    The National Cancer Institute (NCI) invites applications for the funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer." This initiative aims to support the validation of molecular, cellular, and imaging markers (biomarkers) and related assays for cancer detection, diagnosis, prognosis, treatment monitoring, and prevention. The funding mechanism operates in two phases: the UH2 phase focuses on analytical validation of assays within two years, while the UH3 phase supports clinical validation for up to three years. Eligible applicants include higher education institutions, nonprofits, and local governments. Applications must demonstrate analytical and clinical validation capabilities, addressing specific milestones for transitioning between phases. The initiative emphasizes teamwork among oncologists, statisticians, and laboratory scientists to ensure the successful integration of validated assays into clinical studies. Award amounts for the UH2 phase can reach $275,000, while the UH3 phase allows up to $250,000 per year. The NOFO is designed to foster advancements in cancer research and treatment through structure and rigorous validation of biomarkers and assays.
    Similar Opportunities
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at facilitating the clinical validation of biomarkers and assays for cancer management through a Cooperative Agreement mechanism. This initiative seeks to support projects that optimize and validate existing assays for cancer detection, diagnosis, and treatment response evaluation, emphasizing collaboration among multidisciplinary teams of scientific investigators, oncologists, and clinical laboratory scientists. With a maximum funding amount of $250,000 per year available until the application deadline of October 14, 2026, interested applicants are encouraged to demonstrate prior analytical validation of their assays and provide a comprehensive plan for further optimization and integration into clinical studies. For more information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-314.html.
    Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for revision applications aimed at validating biomarker assays developed through NIH-supported research grants, specifically under the R01 mechanism, with a focus on enhancing their clinical application for cancer detection and treatment. This initiative seeks to accelerate the translation of molecular, cellular, and imaging markers into clinical settings, encouraging multidisciplinary collaborations among scientists, clinicians, and laboratory experts to adapt and validate these biomarkers for various cancer-related purposes. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with funding available up to $150,000 for a project period of up to three years. Interested parties should note that the application deadline is October 13, 2026, and can find further details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)" aimed at supporting extramural research that addresses challenges in clinical assay development due to preanalytical variability in biospecimens. The initiative seeks to investigate how factors such as biospecimen collection, processing, and storage impact the reliability of clinical biomarker assays, particularly in the context of cancer diagnosis and treatment. This funding opportunity is critical for enhancing the reliability of cancer research and improving patient outcomes through the standardization of best practices in biospecimen handling. Eligible applicants can receive up to $250,000 per year for a maximum of five years, with proposals due by September 13, 2024. For further inquiries, interested parties may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" initiative, which is part of the Innovative Molecular Analysis Technologies (IMAT) Program. This funding opportunity aims to support exploratory research projects that address significant gaps in current cancer research methodologies, focusing on the development and validation of novel technologies that enhance the understanding and treatment of cancer, including early detection, screening, and addressing health disparities. Eligible applicants can request up to $300,000 annually for a project period not exceeding three years, with a total of approximately $4.3 million available for 10 anticipated awards in fiscal year 2025. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) for the development and screening of assays aimed at discovering small molecules that can serve as chemical probes, drugs, or immunomodulators. This initiative seeks to support research that elucidates disease biology and therapeutic targets, particularly focusing on cancer-related applications, including the development of assays, high-throughput screening, hit validation, and optimization of lead compounds. The opportunity is open to a wide range of eligible applicants, including educational institutions, nonprofits, and tribal organizations, with no cost-sharing requirement and a project period of up to three years. Interested parties should submit their applications electronically through Grants.gov by the deadline of September 7, 2026, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on developing and validating innovative technologies to enhance the quality of biospecimens used in cancer research, specifically addressing pre-analytical variations that can compromise sample integrity. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and seeks projects that demonstrate preliminary data supporting their feasibility, with a funding ceiling of $300,000 per year for up to three years. Applications are due by October 1, 2024, and interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html.
    Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pragmatic Trials across the Cancer Control Continuum" (UG3/UH3), aimed at accelerating the development of evidence-based cancer interventions that reflect the diversity of the U.S. population. This initiative seeks applications that propose interventions designed to improve cancer-related outcomes through pragmatic trial designs, with a particular focus on addressing health disparities among underrepresented populations. The funding opportunity allows for a total of up to $500,000 annually for the UG3 phase and $750,000 for the UH3 phase, with applications accepted until November 17, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance molecular and cellular analysis capabilities in cancer research, with an emphasis on technical innovation and addressing cancer health disparities. The total funding available is approximately $4.2 million, with individual grants of up to $150,000 per year for a maximum of three years. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html.